For the past nine months my 18-year-old son, Jude, has been taking a pollen immunotherapy tablet called Grazax. He developed hay fever in primary school but it got worse as he progressed through ...

Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company ...

Market OverviewThe global Allergic Rhinitis Drugs Market is valued at USD 1.90 Billion in 2024 and is projected to reach a value of USD 2.868 Billion by 2035 at a CAGR (Compound Annual Growth Rate) of ...

As of April 15 at 4:00:00 PM EDT. Market Open.